Ignite Creation Date:
2024-05-06 @ 6:55 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05833893
Status:
RECRUITING
Last Update Posted:
2023-04-27
First Post:
2023-02-25
Brief Title:
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NKT-cell Lymphoma
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NKT-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with newly diagnosed pathologically confirmed NKT-cell lymphoma of stage III-IV treated with XCOPL regimen 3 weeks for a cycle with a total of 6-8 cycles
Detailed Description:
Patients with newly diagnosed pathologically confirmed NKT-cell lymphoma of stage III-IV treated with XCOPL regimen 3 weeks for a cycle with a total of 6-8 cycles Initial safety and PET-CT assessment were performed after 3 cycles of treatment which could be delayed until 4 cycles of treatment in special cases Patients who achieved partial remission or above will continue the original regimen and patients who did not achieve partial remission or above will perform re-biopsy and be excluded from the group Patients who remain partial remission by PET-CT evaluation after 6 cycles may switch to a second-line regimen referring to NCCN guidelines GDP regimen combined with selinexor is recommended Chemotherapy will be performed for up to 8 cycles followed by autologous or allogeneic hematopoietic stem cell transplantation after which follow-up period was entered It is recommended to perform ultrasound or CT evaluation peripheral blood ctDNA and EBV copy number every three months during the first year of follow-up and PET-CT evaluation every half a year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None